Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines.

IF 5.9 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Hepatology International Pub Date : 2024-06-01 DOI:10.1007/s12072-023-10634-6

Wei Teng, Ting-Tsung Chang, Hwai-I Yang, Cheng-Yuan Peng, Chien-Wei Su, Tung-Hung Su, Tsung-Hui Hu, Ming-Lung Yu, Hung-Chih Yang, Jaw-Ching Wu

引用次数: 0

查看原文本刊更多论文

更正：预测 HCC 的风险评分和抗病毒治疗对处于治疗指南灰色地带的慢性乙型肝炎患者的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatology International 医学-胃肠肝病学

CiteScore

10.90

自引率

3.00%

发文量

167

审稿时长

6-12 weeks

期刊介绍： Hepatology International is the official journal of the Asian Pacific Association for the Study of the Liver (APASL). This is a peer-reviewed journal featuring articles written by clinicians, clinical researchers and basic scientists is dedicated to research and patient care issues in hepatology. This journal will focus mainly on new and emerging technologies, cutting-edge science and advances in liver and biliary disorders. Types of articles published: -Original Research Articles related to clinical care and basic research -Review Articles -Consensus guidelines for diagnosis and treatment -Clinical cases, images -Selected Author Summaries -Video Submissions